Comparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD

Фаза 4 Завершено NCT02977299

Кратко

This is a multi-site, randomized, open-label, effectiveness trial comparing three treatment arms for Major Depressive Disorder (MDD) patients with TRD who are currently on ongoing, stable and adequate antidepressant therapy (ADT). Adequate ADT is defined as a therapeutically sufficient dose for a sufficient treatment period, which would be expected to be effective as listed in the MGH Antidepressant Treatment Response Questionnaire (ATRQ). Patients will be randomized in a 1:1:1 fashion to one of three open-label treatment arms: a) aripiprazole augmentation, b) rTMS augmentation, and c) switching to venlafaxine XR or Duloxetine.

Montgomery-Asberg Depression Rating Scale (MADRS)

8 weeks · points

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Другие исследования по этому заболеванию

• CBT+ for Depression — University of Wisconsin, Madison
• Probing the Dorsolateral Prefrontal Cortex and Central Executive Network for Improving Neu — Stanford University
• Severe Asthma, MepolizumaB and Affect: SAMBA Study — University Hospital Southampton NHS Foundation Trust
• Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for — Levomecor Inc.
• A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major De — Levomecor Inc.
• Individualized Functional Connectivity Targeting in aiTBS for Depression — Brigham and Women's Hospital

Все исследования